The clinical profile of benralizumab in the management of severe eosinophilic asthma
Despite several therapeutic choices, 10–20% of patients with severe uncontrolled asthma do not respond to maximal best standard treatments, leading to a healthcare expenditure of up to 80% of overall costs for asthma. Today, there are new important therapeutic strategies, both pharmacological and in...
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Makale |
| Dil: | English |
| Baskı/Yayın Bilgisi: |
SAGE Publishing
2016-12-01
|
| Seri Bilgileri: | Therapeutic Advances in Respiratory Disease |
| Online Erişim: | https://doi.org/10.1177/1753465816667659 |